Zika virus is a mosquito-borne infection that can cause severe birth defects in pregnant women, such as microcephaly (a condition where a baby’s head is smaller than expected). In response to the Zika virus outbreak, scientists and researchers worked on developing a vaccine to prevent the infection. For immunisation and protection against infections brought on by the Zika virus, zika vaccines are being developed. This virus, which is a member of the Flavivirus genus, is spread by Aedes mosquitoes. Moreover, the virus can be passed from an infected pregnant woman to the foetus by a blood transfusion, sexual contact, or other means. Viral DNA is discovered using PCR to validate the infection’s diagnosis. Just one in four zika infected individuals will experience symptoms, though. Since most cases of the zika virus were asymptomatic, the World Health Organization (WHO) ruled in November 2016 that the infection is no longer a Public Health Emergency of International Concern (PHEIC).
Note: Updated Version 2023 is Available
Click Here To Get The Sample Copy of The Report:
https://www.coherentmarketinsights.com/insight/request-sample/413
The Zika virus began a significant ongoing outbreak in Brazil in April 2015, which later spread to South and Central America. This outbreak resulted in a mild illness (fever, rashes, joint pains, conjunctivitis, nausea, and muscle pain), but more recent outbreaks have shown serious complications in infants born to infected mothers, including microcephaly, Guillain-Barré syndrome, and various congenital neurological abnormalities. In Brazil in 2015, it was discovered and stated that there is a connection between the zika virus and microcephaly and Guillain-Barré syndrome.
In the United States, 70 new cases of the zika virus infection were recorded in 2015, while 41,181 cases were reported in 2016, according to the Centers for Disease Control and Prevention (CDC). A significant contributor to 2015’s lower incidence rate is a lack of reporting. An increase in knowledge may lead to increased diagnoses and reports, which would drive up demand for zika vaccines globally.
The zika virus can be killed by an extract of the Australian San Francisco plant (Codiaeum variegatum), according to researchers at Queensland University of Technology. Without harming the host cells, this extract can halt the virus’s replication and arrest it.
Zika Vaccines Market Taxonomy:
against There are various vaccines that offer defence against the Zika virus:
- DNA-based vaccines
- Inactivated vaccines
- Live-attenuated vaccines
- mRNA vaccines
- Genetically engineered vaccines
Global market by application:
- Therapeutic Vaccines
- Preventive Vaccines
Global market by end user:
- Hospitals
- Clinics
Zika vaccine sales will climb as a result of rising zika incidence and ongoing expansion of human clinical trials.
As of March 2016, 67 businesses and academic institutions were engaged in various R&D initiatives and clinical studies that advanced the creation of efficient vaccines against the zika virus. Inovio Pharmaceuticals’ GLS-5700, a zika vaccine under development, received FDA approval for its first human clinical study in June 2016. In addition, a grant for the Vaccine Research Center of NIAID’s phase 2 clinical trials of a DNA vaccine was granted in 2017. (VRC).
Controlling the incidence rate of zika infection would be made easier by raising public knowledge. With the help of its Zika Strategic Response Strategy and Joint Plan, the WHO launched a global strategy for raising public awareness in February 2016. This plan covers every step that needs to be performed in the event of an infection. A training programme was created in June 2016 by the WHO Regional Office for Europe in order to raise awareness with the release of the Zika Risk Assessment for European Region.
As of March 2016, 67 businesses and academic institutions were engaged in various R&D initiatives and clinical studies that advanced the creation of efficient vaccines against the zika virus. Inovio Pharmaceuticals’ GLS-5700, a zika vaccine under development, received FDA approval for its first human clinical study in June 2016. In addition, a grant for the Vaccine Research Center of NIAID’s phase 2 clinical trials of a DNA vaccine was granted in 2017. (VRC).
The zika vaccine market is constrained by the high investment costs necessary for R&D and the creation of efficient zika virus vaccines.
While the majority of Zika virus cases are found in tropical countries like Brazil, Paraguay, Venezuela, Colombia, and Suriname, there is a higher risk of mosquito-borne illnesses in tropical U.S. states like Texas and Florida. In the subregion, which includes Brazil, Argentina, Peru, and Ecuador, there were approximately 1,246 suspected and confirmed cases recorded between epidemiological week (EW) 10 and EW 14 of 2016.
Competitive Environment
Biken Inc, Sanofi S.A., Inovio Pharmaceuticals, Cerus Corporation, Bharat Biotech International Pvt. Ltd, GlaxoSmithKline plc, GeneOne Life Science, Immunovaccine Inc., and NewLink Genetics Corp.are a few of the major companies in the zika vaccine industry. To achieve immunogenicity against the zika virus, the corporations started a variety of R&D initiatives and clinical trials. With the release of Dengvaxia (the dengue vaccine), Sanofi S.A. began a project to research and develop vaccines. This effort will help the firm better understand the Zika virus and create a vaccine that is effective against it. In Puerto Rico, Inovio Pharmaceuticals started a clinical trial of the zika vaccine (GLS-5700) in August 2016. If successful, this experiment might provide Inovio’s vaccine a boost because the zika outbreak in Puerto Rico at the time was spreading quickly. This might help the trial evaluate the vaccine’s actual efficacy and safety. Fast advancement in clinical studies and approval would accelerate the market expansion for zika vaccines.
The Global Zika Vaccine Market size was valued at $14,500 million in 2022 and is expected to reach $18,697 million by end of 2030, growing at a CAGR of 7.67%.
𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐓𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐩𝐨𝐫𝐭 𝐖𝐢𝐭𝐡 𝐔𝐩 𝐓𝐨 𝟐𝟓% 𝐎𝐅𝐅 @
https://www.coherentmarketinsights.com/insight/buy-now/413
| The market size value in 2023 |
Table of Contents with Major Points:
Executive Summary
- Introduction
- Key Findings
- Recommendations
- Definitions and Assumptions
Executive Summary
Market Overview
- Definition of Zika Vaccines Market
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Trends and Developments
Key Insights
- Key Emerging Trends
- Key Developments Mergers and Acquisition
- New Product Launches and Collaboration
- Partnership and Joint Venture
- Latest Technological Advancements
- Insights on Regulatory Scenario
- Porters Five Forces Analysis
Qualitative Insights Impact of COVID-19 on Global Zika Vaccines Market
- Supply Chain Challenges
- Steps taken by Government/Companies to overcome this impact
- Potential opportunities due to COVID-19 outbreak
Conclusion
Appendix
- Data Sources
- Abbreviations
- Disclaimer
TOC Continued…!
Why Choose Coherent Market Insights?
☛ Identified business opportunities – Our market research report can be used to analyze potential markets and new products. It can give information about customer needs, preferences, and attitudes. Also, it compare products and services.
☛ A clear understanding of your customers – A market report gives company’s marketing department an in-depth picture about customers’ needs and wants. This knowledge can be used to improve products, prices, and advertising.
☛ Clear data-driven insights – Our Market research encompasses a wide range of activities, from determining market size and segment to forecasting demand, and from identifying competitors to monitoring pricing. All of these are quantified and measurable which means that gives you a clear path for building unique decisions based on numbers.
Ask For Discount Before Purchasing This Premium Report :
https://www.coherentmarketinsights.com/insight/request-discount/413
Explore More Related Insights:
India immune oncology drugs market
Halal nutraceuticals and vaccines market
Veterinary dermatology drugs market
Ambulatory surgical center market
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Mr Shah
Coherent Market Insights
533 Airport Boulevard, Suite 400, Burlingame,
CA 94010, United States.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837